Hikal signed ten year multi product deal with a leading global pharmaceutical innovator company. This contract entails the development and supply of a portfolio of niche APIs over a period of ten years. The development will start this year and commercial supplies will commence post successful development and plant commercialisation estimated to be in Fiscal Year 2024 onwards. With this deal, company is entering into a niche area of chemistry and products thereby bolstering its Animal Health vertical. Hikal and its customer will be jointly investing at its Panoli, Gujarat site to setup a multipurpose manufacturing asset for manufacturing of these API's.